CytomX Therapeutics Inc (CTMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $444.73M
Last updated: Nov 17, 2026 at 11:04 AM ET
CytomX Therapeutics Inc (CTMX) Earnings: Report Dates and Results
CytomX Therapeutics (CTMX) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, CytomX Therapeutics reported EPS of -$0.09, below the -$0.07 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CTMX has an expected report date of Mar 15, 2027.
CTMX Earnings Call
The latest CTMX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, CTMX beat 23 and missed 16. Revenue for the quarter ended Sep 30, 2026 was $1.69M, down 71.6% from $5.96M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.09 | -$0.07 | -$0.11 - $0.03 | -28.57% | Miss | N/A | 7 | 4 up, 1 down | Nov 5, 2026 | $1.69M |
| Jun 30, 2026 | -$0.09 | -$0.11 | -$0.13 - -$0.09 | +18.18% | Beat | N/A | 6 | 2 up, 4 down | Aug 6, 2026 | $1.42M |
| Mar 31, 2026 | -$0.10 | -$0.11 | -$0.16 - -$0.08 | +9.09% | Beat | -137.0% | 8 | 2 up, 2 down | May 7, 2026 | $10.26M |
| Dec 31, 2025 | -$0.22 | -$0.09 | -$0.17 - -$0.03 | -134.79% | Miss | -195.7% | 8 | 0 up, 4 down | Mar 16, 2026 | $663000 |
| Sep 30, 2025 | -$0.09 | -$0.04 | -$0.09 - $0.00 | -125.00% | Miss | -228.6% | 7 | 1 up, 0 down | Nov 6, 2025 | $5.96M |
| Jun 30, 2025 | $0.00 | -$0.06 | -$0.12 - $0.02 | +98.00% | Beat | N/A | 6 | 0 up, 5 down | Aug 7, 2025 | $18.66M |
| Mar 31, 2025 | $0.27 | $0.13 | -$0.08 - $0.25 | +104.24% | Beat | +58.8% | 5 | 1 up, 0 down | May 12, 2025 | $50.92M |
| Dec 31, 2024 | $0.23 | -$0.11 | -$0.16 - -$0.01 | +309.09% | Beat | +2200.0% | 4 | 1 up, 0 down | Mar 6, 2025 | $38.09M |
| Sep 30, 2024 | $0.07 | -$0.13 | -$0.28 - -$0.09 | +153.85% | Beat | +75.0% | 7 | 0 up, 0 down | Nov 7, 2024 | $33.43M |
| Jun 30, 2024 | -$0.08 | -$0.06 | -$0.25 - -$0.01 | -33.33% | Miss | N/A | 6 | 0 up, 0 down | Aug 8, 2024 | $25.11M |
| Mar 31, 2024 | $0.17 | -$0.06 | -$0.22 - $0.02 | +383.33% | Beat | N/A | 6 | 0 up, 1 down | May 8, 2024 | $41.46M |
| Dec 31, 2023 | $0.01 | -$0.03 | -$0.24 - $0.12 | +133.33% | Beat | N/A | 7 | 0 up, 0 down | Mar 11, 2024 | $26.61M |
| Sep 30, 2023 | $0.04 | -$0.21 | -$0.41 - -$0.05 | +119.05% | Beat | N/A | 9 | 0 up, 0 down | Nov 7, 2023 | $26.38M |
| Jun 30, 2023 | -$0.02 | -$0.20 | -$0.39 - -$0.13 | +90.00% | Beat | N/A | 8 | 0 up, 0 down | Aug 8, 2023 | $24.72M |
| Mar 31, 2023 | -$0.05 | -$0.11 | -$0.33 - $0.14 | +54.55% | Beat | N/A | 8 | 2 up, 1 down | May 9, 2023 | $23.50M |
| Dec 31, 2022 | -$0.43 | -$0.24 | -$0.44 - -$0.14 | -79.17% | Miss | N/A | 9 | 0 up, 0 down | Mar 27, 2023 | $20.12M |
| Sep 30, 2022 | -$0.35 | -$0.33 | -$0.44 - -$0.19 | -6.06% | Miss | N/A | 9 | 0 up, 0 down | Nov 8, 2022 | $11.15M |
| Jun 30, 2022 | -$0.37 | -$0.40 | -$0.51 - -$0.18 | +7.50% | Beat | N/A | 9 | 1 up, 0 down | Aug 4, 2022 | $12.85M |
| Mar 31, 2022 | -$0.37 | -$0.36 | -$0.44 - -$0.26 | -2.78% | Miss | N/A | 9 | 0 up, 0 down | May 5, 2022 | $9.04M |
| Dec 31, 2021 | -$0.40 | -$0.28 | -$0.40 - $0.23 | -42.86% | Miss | N/A | 9 | N/A | Mar 1, 2022 | N/A |
| Sep 30, 2021 | -$0.35 | -$0.30 | -$0.43 - -$0.16 | -16.67% | Miss | N/A | 8 | N/A | Nov 4, 2021 | $17.59M |
| Jun 30, 2021 | -$0.30 | -$0.31 | -$0.52 - -$0.16 | +3.23% | Beat | N/A | 11 | N/A | Aug 5, 2021 | $16.29M |
| Mar 31, 2021 | -$0.26 | -$0.35 | -$0.52 - -$0.06 | +25.71% | Beat | -200.0% | 11 | N/A | May 6, 2021 | $15.97M |
| Dec 31, 2020 | -$0.32 | -$0.50 | -$1.16 - -$0.32 | +36.00% | Beat | N/A | 10 | N/A | Feb 24, 2021 | N/A |
| Sep 30, 2020 | -$0.32 | -$0.49 | -$0.79 - -$0.31 | +34.69% | Beat | N/A | 10 | N/A | Nov 5, 2020 | $17.79M |
| Jun 30, 2020 | -$0.34 | $0.03 | -$0.81 - $1.64 | N/A | N/A | N/A | 10 | N/A | Aug 6, 2020 | $16.61M |
| Mar 31, 2020 | $0.26 | -$0.51 | -$0.66 - $0.18 | +150.98% | Beat | N/A | 11 | N/A | May 7, 2020 | $49.59M |
| Dec 31, 2019 | -$0.78 | -$0.47 | -$0.84 - -$0.19 | -65.96% | Miss | N/A | 11 | N/A | Feb 27, 2020 | N/A |
| Sep 30, 2019 | -$0.52 | -$0.46 | -$0.88 - -$0.26 | -13.04% | Miss | N/A | 10 | N/A | Nov 7, 2019 | $10.71M |
| Jun 30, 2019 | -$0.64 | -$0.59 | -$0.81 - -$0.34 | -8.47% | Miss | N/A | 11 | N/A | Aug 7, 2019 | $9.01M |
| Mar 31, 2019 | -$0.31 | -$0.52 | -$0.70 - -$0.41 | +40.38% | Beat | N/A | 11 | N/A | May 9, 2019 | $29.48M |
| Dec 31, 2018 | -$0.72 | -$0.48 | -$0.75 - -$0.22 | -50.00% | Miss | -2500.0% | 10 | N/A | Feb 27, 2019 | $11.47M |
| Sep 30, 2018 | -$0.53 | -$0.41 | -$0.67 - $0.00 | -29.27% | Miss | N/A | 10 | N/A | Nov 6, 2018 | $12.51M |
| Jun 30, 2018 | -$0.35 | -$0.42 | -$0.60 - $0.36 | +16.67% | Beat | N/A | 8 | N/A | Aug 8, 2018 | $21.34M |
| Mar 31, 2018 | -$0.40 | -$0.56 | -$1.15 - -$0.04 | +28.57% | Beat | N/A | 8 | N/A | May 9, 2018 | $14.18M |
| Dec 31, 2017 | $0.03 | -$0.46 | -$0.70 - -$0.25 | +106.52% | Beat | N/A | 8 | N/A | Mar 7, 2018 | $27.07M |
| Sep 30, 2017 | -$0.28 | -$0.22 | -$0.36 - $0.07 | -27.27% | Miss | N/A | 7 | N/A | Nov 7, 2017 | $24.14M |
| Jun 30, 2017 | -$0.69 | -$0.33 | -$0.56 - -$0.18 | -109.09% | Miss | N/A | 5 | N/A | Aug 7, 2017 | $8.75M |
| Mar 31, 2017 | -$0.23 | -$0.51 | N/A | +54.90% | Beat | N/A | N/A | N/A | May 5, 2017 | $11.65M |
| Dec 31, 2016 | -$0.39 | -$0.42 | N/A | +7.14% | Beat | N/A | N/A | N/A | Mar 2, 2017 | $6.27M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.04, after $0.39 the year before. It was -$1.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.04 | -110.6% |
| Dec 31, 2024 | $0.39 | N/A |
| Dec 31, 2023 | -$0.02 | N/A |
| Dec 31, 2022 | -$1.52 | N/A |
| Dec 31, 2021 | -$1.31 | N/A |
| Dec 31, 2020 | -$0.72 | N/A |
| Dec 31, 2019 | -$2.25 | N/A |
| Dec 31, 2018 | -$2.00 | N/A |
| Dec 31, 2017 | -$1.17 | N/A |
| Dec 31, 2016 | -$1.62 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,511 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,716 | 10 | |
| 2025Q4 | Dec 31, 2025 | 7,566 | 13 | |
| 2025Q3 | Sep 30, 2025 | 4,826 | 10 | |
| 2025Q2 | Jun 30, 2025 | 4,264 | 10 | |
| 2024Q4 | Dec 31, 2024 | 3,993 | 8 | |
| 2024Q2 | Jun 30, 2024 | 3,569 | 6 |
2026Q3 Earnings Call
Opening remarks
Christopher W. Ogden CFO Thank you. Good afternoon, and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC, at sec.gov. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. Earlier this afternoon, we filed our quarterly report on Form 10-Q for Q3 2026 and issued a press release with a summary of our third quarter 2026 financial results and business highlights. We encourage everyone to read today's filing and press release. Additionally, the recording of this call and our SEC filings can be found under the Investors and News section of our website. With me on the call today is Dr. Sean McCarthy, CytomX's Chief Executive Officer and Chairman. Sean will provide an update on our pipeline and company progress before I cover the financials for the quarter. We will then conclude with a Q&A session. With that, I will turn the call over to Sean.
Sean A. McCarthy CEO and Chairman Thanks, Christopher, and good afternoon, everyone. We are very pleased to be here today to provide an update on our third quarter developments and what continues to be a highly productive year for CytomX as we advance our lead program, Varseta-M, toward its first potential registrational study in the first half of 2027. Varseta-M is an EpCAM-targeting topo-1 antibody-drug conjugate with strong potential in colorectal cancer and potentially other solid tumors. Importantly, to our knowledge, Varseta-M is first in class as the only EpCAM-directed ADC in clinical development. Varseta-M has been intentionally designed and uniquely enabled by our PROBODY platform, creating a significant opportunity for differentiation and long-term value creation. Strategically, we are initially developing Varseta-M in metastatic colorectal cancer as the lead indication. Our sense of urgency for Varseta-M is driven by the significant unmet need in colorectal cancer, which is the second-leading cause of cancer death in the United States and worldwide. Varseta-M is on the leading edge of ADC innovation in CRC and has the potential to be one of the first monotherapy ADCs to market for the treatment of this very challenging cancer type. In terms of commercial potential, there are an estimated 35,000 addressable patients in the United States with third-line or later CRC.
Frequently Asked Questions About CTMX
When is CytomX Therapeutics's next earnings date?
CytomX Therapeutics's next earnings report is expected for Mar 15, 2027.
Did CTMX beat earnings estimates last quarter?
No. CytomX Therapeutics reported EPS of -$0.09 for the quarter ended Sep 30, 2026, below the -$0.07 estimate by 28.57%.
What EPS do analysts expect from CTMX next quarter?
The consensus EPS estimate for CytomX Therapeutics for the quarter ending Dec 31, 2026 is -$0.10 from 10 analysts, with estimates from -$0.12 to -$0.06.
How often does CTMX beat earnings estimates?
CytomX Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +31.28%.
CTMX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors